Author: Lucy Jean Sannes, Ph.D., M.B.A.
FIGURES
Figure 1.1. Number of Abstracts Per Year from PubMed Search for “epigenetic OR epigenetics OR epigenomic OR epigenomics” 2
Figure 2.1. The Epigenetic Pathway 6
Figure 2.2. The Increasing Structural Complexity of Genetic Information from the Double-Helical Structure of DNA, through Nucleosome and Chromatin Structures, to the Chromosome 8
Figure 2.3. Schematic of the Nucleosome Showing Types of Post-Translational Modifications That Can Occur and the Enzymes Responsible for Them 8
Figure 2.4. Proposed Mechanism of Action of DNA Methylation Inhibitors in Cancer Therapy 16
TABLES
Table 2.1. Methods Available to Analyze DNA Methylation 10
Table 3.1. Companies Developing and/or Offering Epigenetic-Based Diagnostic Tests 20
Table 3.2. Clinical Laboratories Developing and/or Offering Epigenetic-Based Diagnostic Tests for Cancer 36
Table 3.3. Epigenetic Agreements 38
Table 4.1. Incidence of Hematological Cancers in the United States 45
Table 4.2. Incidence of Selected Cancers (Solid Tumors) in the United States (2009) 46
Table 5.1. Companies Marketing and Developing DNA Methylation Inhibitors 50
Table 5.2. Companies Marketing and Developing HDAC Inhibitors 53
Table 5.3. Companies Developing Novel Therapies Targeting Sirtuins 62
Table 5.4. Companies Developing Other Emerging Epigenetic Therapies 75
Table 6.1. Reported 2009 Sales of Approved Epigenetic Drugs 81
Table 6.2. Selected Epigenetic Therapeutic Agreements 92
Table 6.3. Selected Companies That Have Out-Licensed Epigenetic Drug Technology/Compounds and No Longer Appear to be Active in the Epigenetics Field 96